Role of imaging for eligibility and safety of a-NGF clinical trials

Nerve growth factor (a-NGF) inhibitors have been developed for pain treatment including symptomatic osteoarthritis (OA) and have proven analgesic efficacy and improvement in functional outcomes in patients with OA. However, despite initial promising data, a-NGF clinical trials focusing on OA treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Roemer, Frank W., Hochberg, Marc C., Carrino, John A., Kompel, Andrew J., Diaz, Luis, Hayashi, Daichi, Crema, Michel D., Guermazi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Addressing the Challenges Associated with the Development, Testing and Approval of Novel Therapeutics for Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240557/
https://www.ncbi.nlm.nih.gov/pubmed/37284331
http://dx.doi.org/10.1177/1759720X231171768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240557/
https://www.ncbi.nlm.nih.gov/pubmed/37284331
http://dx.doi.org/10.1177/1759720X231171768

Ejemplares similares